To summarize, clinical trials have demonstrated that SGLT2 inhibitors significantly improve cardiovascular outcomes in patients with T2DM by reducing major adverse cardiovascular events, lowering blood pressure, and favorably modifying lipid profiles. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.